The EFFECT filing one day before this S-1 means the resale shares are immediately tradable, creating immediate overhang of ~12% of shares outstanding. Monitor for selling by institutional holders (Anson, Intracoastal) and any update on the $10M BioTissue Clearance Payment — failure to pay could trigger forfeiture of extension payments and immediate acceleration of the full liability. The DOJ CID under the False Claims Act adds material legal overhang; any subpoena expansion or settlement discussion would be a negative catalyst.
Executive Summary
BioStem Technologies filed an S-1 registration statement for the resale of up to 2,224,270 shares by selling stockholders, following a September 2026 private placement that raised gross proceeds of approximately $3.0M at $4.08/share with warrants exercisable at $3.83. The filing comes one day after the registration was declared effective (EFFECT filed September 29, 2026), meaning the resale shares are immediately eligible for trading. The company faces severe financial distress: H1 2026 revenue collapsed 48% YoY to $14.0M, net loss was $17.8M, and the auditor has issued a going-concern opinion with a $21.2M accumulated deficit and a $10M Clearance Payment due to BioTissue that remains unpaid.
Key Financial Metrics
Key Facts
- S-1 registers 2,224,270 shares for resale by selling stockholders from a September 2026 PIPE at $4.08/share with warrants at $3.83
- Registration was declared effective on September 29, 2026 (EFFECT filed), making resale shares immediately tradable
- H1 2026 revenue fell 48% YoY to $14.0M; net loss of $17.8M vs. $3.9M profit in H1 2025
- Accumulated deficit of $38.97M as of June 30, 2026; going-concern opinion from KPMG
- $10M Clearance Payment to BioTissue for Catalyze product rights remains unpaid and overdue
- Cash burn: cash balance fell from $29.5M (Dec 2025) to $7.0M (June 2026); operating cash outflow of $6.4M in H1 2026
- CMS reimbursement change (flat $127.14/sq cm effective Jan 2026) cut physician office revenue per sq cm by up to 95%
- DOJ Civil Investigative Demand received in September 2026 under False Claims Act regarding pricing and ASP reporting
- CEO and COO hold Series A-1 Preferred shares granting effective control (~66% voting power as a group)
- CEF facility with Roth Capital for up to $40M established but subject to Nasdaq 19.99% cap of 3.59M shares
Financial Impact
Revenue decline of 48% YoY in H1 2026 ($14.0M vs $26.9M); net loss swing of $21.7M from profit to loss; cash burn of $22.6M in H1 2026; $10M Clearance Payment obligation overdue
Risk Factors
- Immediate resale overhang of 2.22M shares (~12% of float) from institutional PIPE investors
- Going-concern risk: cash balance of $7.0M insufficient to cover $10M Clearance Payment and ongoing losses
- DOJ False Claims Act investigation could result in material penalties or exclusion from federal healthcare programs
- CMS reimbursement changes have permanently impaired physician office revenue stream (down 93% YoY in H1 2026)
- Concentrated voting control by CEO/COO (66% voting power) limits minority shareholder influence
- Cannell SPA anti-dilution protection at $3.35/share with $0.70 floor restricts future equity raising
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1 Filing (Primary) | 0001213900-26-106555 |
| Document: ea030747301ex-fee.htm | 0001213900-26-106555 |
| Document: ea030747301ex5-1.htm | 0001213900-26-106555 |
| Document: ea030747301ex23-2.htm | 0001213900-26-106555 |
| Document: ea030747301ex23-1.htm | 0001213900-26-106555 |
| Document: 0001213900-26-106555-index-headers.html | 0001213900-26-106555 |
| Document: 0001213900-26-106555-index.html | 0001213900-26-106555 |
| Document: 0001213900-26-106555.txt | 0001213900-26-106555 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | EFFECT | $2.25 $2.11 | ▲ +6.22% | ▲ +5.14% | $1.55 (+31.11%) |
Oct 2, 2026 23d ago | S-1 | $2.76 $2.47 | ▲ +10.34% | ▲ +10.89% | $1.55 (+43.74%) |
Sep 30, 2026 25d ago | 8-K | $3.07 $2.73 | ▲ +11.07% | ▲ +11.81% | $1.55 (+49.51%) |
Sep 30, 2026 26d ago | EFFECT | $3.09 $3.07 | ▲ +0.65% | ▲ +0.83% | $1.55 (+49.84%) |
Sep 21, 2026 4w ago | Press Release | $3.98 $3.80 | ▼ −4.52% | ▼ −3.80% | $1.55 (−61.06%) |
Sep 18, 2026 5w ago | S-1 | $4.40 $3.98 | ▲ +9.55% | ▲ +9.53% | $1.55 (+64.77%) |
Sep 18, 2026 5w ago | Press Release | $4.74 $4.40 | ▲ +7.17% | ▲ +8.72% | $1.55 (+67.30%) |
Aug 14, 2026 10w ago | 3 | $3.00 $3.15 | ▲ +5.00% | ▲ +5.68% | $1.55 (−48.33%) |
Aug 14, 2026 10w ago | 3 | $3.00 $3.15 | ▲ +5.00% | ▲ +5.68% | $1.55 (−48.33%) |
Jul 29, 2026 12w ago | S-1 | $3.29 $3.20 | ▲ +2.74% | ▲ +4.41% | $1.55 (+52.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers